Lucentis ranibizumab regulatory update

The U.K.'s NICE issued final guidance recommending against Lucentis ranibizumab from Novartis to treat diabetic macular edema (DME). The committee said Novartis did not provide a "true reflection" of Lucentis' cost-effectiveness compared with laser photocoagulation, the standard of care. NICE concluded that the incremental cost-effectiveness

Read the full 452 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE